Gazella Biotech is a USC spinoff that develops advanced therapies for the treatment of metabolic diseases through innovative approaches.
Gazella develops drugs to improve people’s lives, making new treatments accessible to patients.
Our leadership team
Mario Grande, CEO
Graduate in Business Administration and Management. More than 15 years of experience in the Pharma & Biotech industry, manager in American and European multinationals. Serial entrepreneur and co-founder of several startups in the Pharma & Life Sciences sector. Board member in several Life Science and Biotech companies. More than 10 years investing and divesting in the Pharma, Life Sciences and Biotech sector.
Miguel López, CSO
Professor of Physiology. Director of the NeurObesity Laboratory (CiMUS-USC) More than 25 years as a researcher, specialising in the hypothalamic regulation of energy balance. First person to identify AMPK in the hypothalamus as a key factor in the regulation of metabolism. More than 270 publications in high impact journals. His work has been cited 20,000 times. His research has received countless international awards, both as an individual and as the research group he leads.
Expertscape hypothalamus: 1st position worldwide / Expertscape AMPK: 6tht position worldwide
Paco Moreno, CBDO
PhD in Molecular Biology. More than 20 years of professional career in basic research, preclinical research and R&D in the multinational pharmaceutical industry, such as Merck. More than 15 years of experience in the identification, evaluation and selection of Pharma & Life Sciences opportunities as Director of the Science Area and of the investment and technology transfer programmes of the Botín Foundation.